| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
138,763 |
126,627 |
$5.00M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
13,105 |
12,586 |
$1.03M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
12,345 |
11,907 |
$1.01M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
9,495 |
9,148 |
$849K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
54,119 |
26,948 |
$563K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
7,393 |
7,077 |
$547K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,124 |
4,978 |
$286K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
15,090 |
14,493 |
$206K |
| 99381 |
|
2,864 |
2,762 |
$196K |
| 99000 |
|
18,113 |
17,616 |
$179K |
| 99382 |
|
1,295 |
1,267 |
$118K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
9,507 |
9,128 |
$101K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,942 |
6,671 |
$97K |
| 99383 |
|
943 |
921 |
$84K |
| S8301 |
Infection control supplies, not otherwise specified |
6,114 |
5,795 |
$75K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
731 |
691 |
$61K |
| 90461 |
|
7,280 |
6,126 |
$46K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,697 |
1,603 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
950 |
894 |
$36K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,911 |
3,789 |
$29K |
| 99384 |
|
238 |
236 |
$24K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
455 |
442 |
$23K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,960 |
1,774 |
$23K |
| 0071A |
|
529 |
415 |
$17K |
| 0072A |
|
281 |
279 |
$12K |
| 97169 |
|
476 |
469 |
$9K |
| 81002 |
|
2,383 |
2,261 |
$7K |
| 87807 |
|
465 |
444 |
$5K |
| 86328 |
|
57 |
57 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
13 |
13 |
$538.95 |
| 93000 |
|
25 |
25 |
$306.76 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
27 |
21 |
$172.62 |
| 90733 |
|
623 |
606 |
$90.40 |
| 96160 |
|
3,595 |
3,501 |
$20.98 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
318 |
267 |
$4.84 |
| 90697 |
|
2,439 |
2,324 |
$1.10 |
| 90686 |
|
10,523 |
10,286 |
$0.91 |
| 90620 |
|
2,344 |
2,235 |
$0.47 |
| 90715 |
|
2,047 |
1,946 |
$0.36 |
| 90671 |
|
2,306 |
2,161 |
$0.11 |
| 91307 |
|
879 |
718 |
$0.06 |
| 90670 |
|
4,605 |
4,431 |
$0.06 |
| 90734 |
|
2,456 |
2,321 |
$0.06 |
| 90744 |
|
1,141 |
1,103 |
$0.05 |
| 90651 |
|
1,869 |
1,779 |
$0.04 |
| 90696 |
|
1,772 |
1,689 |
$0.03 |
| 90710 |
|
1,845 |
1,759 |
$0.03 |
| 90680 |
|
4,373 |
4,191 |
$0.01 |
| 90633 |
|
4,208 |
4,038 |
$0.01 |
| 90716 |
|
2,014 |
1,925 |
$0.00 |
| 90698 |
|
2,277 |
2,184 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
447 |
441 |
$0.00 |
| 90647 |
|
409 |
396 |
$0.00 |
| 90723 |
|
146 |
142 |
$0.00 |
| 91305 |
|
42 |
41 |
$0.00 |
| 90677 |
|
38 |
38 |
$0.00 |
| 90700 |
|
1,756 |
1,674 |
$0.00 |
| 90649 |
|
1,248 |
1,223 |
$0.00 |
| 90707 |
|
2,024 |
1,934 |
$0.00 |
| 90648 |
|
988 |
933 |
$0.00 |
| 90681 |
|
29 |
27 |
$0.00 |
| 90658 |
|
51 |
51 |
$0.00 |
| 91308 |
|
12 |
12 |
$0.00 |